BRPI0415887A - remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita - Google Patents

remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita

Info

Publication number
BRPI0415887A
BRPI0415887A BRPI0415887-3A BRPI0415887A BRPI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A BR PI0415887 A BRPI0415887 A BR PI0415887A
Authority
BR
Brazil
Prior art keywords
molecular weight
high molecular
removal
weight aggregates
hydroxyapatite chromatography
Prior art date
Application number
BRPI0415887-3A
Other languages
English (en)
Inventor
Shujun Sun
Christopher Gallo
Brian Kelley
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to BR122020007658-5A priority Critical patent/BR122020007658B1/pt
Publication of BRPI0415887A publication Critical patent/BRPI0415887A/pt
Publication of BRPI0415887B1 publication Critical patent/BRPI0415887B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/04—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
    • B01J20/048—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium containing phosphorus, e.g. phosphates, apatites, hydroxyapatites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/282—Porous sorbents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

"REMOçãO DE AGREGADOS DE ELEVADO PESO MOLECULAR USANDO CROMATOGRAFIA DE HIDROXIAPATITA". Esta invenção refere-se à aplicação de cromatografia de hidroxiapatita à purificação de pelo menos um anticorpo a partir de uma preparação contendo agregados de elevado peso molecular. Além disso, esta invenção refere-se a uma integração de cromatografia de hidroxiapatita cerâmica em um protocolo cromatográfico de combinação para a remoção de agregados de elevado peso molecular a partir de uma preparação de anticorpos.
BRPI0415887-3A 2003-10-27 2004-10-06 métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita BRPI0415887B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51401803P 2003-10-27 2003-10-27
US60/514,018 2003-10-27
US52333503P 2003-11-20 2003-11-20
US60/523,335 2003-11-20
PCT/US2004/032883 WO2005044856A2 (en) 2003-10-27 2004-10-06 Removal of high molecular weight aggregates using hydroxyapatite chromatography

Publications (2)

Publication Number Publication Date
BRPI0415887A true BRPI0415887A (pt) 2007-01-09
BRPI0415887B1 BRPI0415887B1 (pt) 2021-01-26

Family

ID=34576743

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0415887-3A BRPI0415887B1 (pt) 2003-10-27 2004-10-06 métodos para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020007658-5A BR122020007658B1 (pt) 2003-10-27 2004-10-06 Método para a remoção de agregados de elevado peso molecular utilizando cromatografia de hidroxiapatita

Country Status (19)

Country Link
US (2) US9469672B2 (pt)
EP (2) EP2336172B1 (pt)
JP (2) JP5004586B2 (pt)
KR (2) KR101321876B1 (pt)
CN (2) CN1898266B (pt)
AU (1) AU2004286938B2 (pt)
BR (2) BRPI0415887B1 (pt)
CA (1) CA2543193C (pt)
CO (1) CO5690649A2 (pt)
DK (2) DK2336172T3 (pt)
EC (1) ECSP066583A (pt)
ES (2) ES2418830T3 (pt)
IL (1) IL175229A (pt)
MX (1) MXPA06004472A (pt)
NZ (1) NZ547315A (pt)
PL (2) PL2336172T3 (pt)
PT (2) PT2336172E (pt)
RU (2) RU2409591C2 (pt)
WO (1) WO2005044856A2 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
CA2543193C (en) * 2003-10-27 2015-08-11 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography
MX2007011129A (es) * 2005-03-11 2007-11-06 Wyeth Corp Un metodo de cromatografia de particion debil.
ES2405079T3 (es) * 2005-06-17 2013-05-30 Wyeth Llc Métodos para purificar anticuerpos de la región Fc
KR20080025174A (ko) * 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
EP1962907A2 (en) * 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
JPWO2007123242A1 (ja) 2006-04-25 2009-09-10 東ソー株式会社 ＩｇＧ精製用分離剤、及びそれを用いたＩｇＧ単量体の精製方法
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
EA017733B1 (ru) * 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
JP2010501623A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ含有タンパク質の精製法
WO2008031020A2 (en) * 2006-09-08 2008-03-13 Wyeth Arginine wash in protein purification using affinity chromatography
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
MY161866A (en) 2006-09-13 2017-05-15 Abbvie Inc Cell culture improvements
US7999085B2 (en) * 2007-01-09 2011-08-16 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of protein by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CA2674213A1 (en) * 2007-01-26 2008-07-31 Merck Serono S.A. Purification of fc-taci fusion proteins using the oilbody technology
EP2226331A4 (en) * 2007-10-26 2012-02-08 Asahi Kasei Chemicals Corp METHOD OF PURIFYING PROTEINS
WO2009126603A1 (en) * 2008-04-08 2009-10-15 Bio-Rad Laboratories, Inc. Chromatography purification of antibodies
US10927144B2 (en) † 2008-08-14 2021-02-23 Genentech, Inc. Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
SG10201702922VA (en) * 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
US10118962B2 (en) * 2008-10-29 2018-11-06 Ablynx N.V. Methods for purification of single domain antigen binding molecules
EP2350130B1 (en) * 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
RU2011137030A (ru) * 2009-03-11 2013-04-20 УАЙТ ЭлЭлСи Способы очистки малых модулярных иммунофармацевтических белков
CA2759502C (en) 2009-04-29 2021-02-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
US9441011B2 (en) 2009-07-03 2016-09-13 Asahi Kasei Chemicals Corporation Method for purification of antibody using porous membrane having amino group and alkyl group both bound to graft chain immobilized on porous substrate
CN104744560A (zh) 2009-10-20 2015-07-01 Abbvie公司 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
SG10201408384PA (en) 2009-12-18 2015-01-29 Novartis Ag Wash solution and method for affinity chromatography
EP2519537A4 (en) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
US8951807B2 (en) 2010-01-15 2015-02-10 Bio-Rad Laboratories, Inc. Surface neutralization of apatite
KR20120132529A (ko) 2010-04-14 2012-12-05 에프. 호프만-라 로슈 아게 면역글로불린 응집물 제거
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
US20110301333A1 (en) * 2010-06-08 2011-12-08 Millipore Corporation Removal of protein aggregates from biopharmaceutical preparations using calcium phosphate salts
US8895707B2 (en) * 2010-08-18 2014-11-25 Bio-Rad Laboratories, Inc. Elution of proteins from hydroxyapatite resins without resin deterioration
JP2013540787A (ja) 2010-11-01 2013-11-07 ディーエスエム アイピー アセッツ ビー．ブイ． 単一ユニットイオン交換クロマトグラフィー抗体精製
EP2670704B1 (en) 2011-02-02 2018-12-12 Bio-Rad Laboratories, Inc. Apatite surface neutralization with alkali solutions
SG10201603931TA (en) * 2011-06-08 2016-07-28 Agency Science Tech & Res Purification Of Biological Products By Constrained Cohydration Chromatography
CN103619868A (zh) * 2011-06-16 2014-03-05 帝斯曼知识产权资产管理有限公司 单一单元色谱抗体纯化
SG10201701224UA (en) 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
EP2855501B1 (en) 2012-05-30 2018-04-25 Bio-Rad Laboratories, Inc. In situ restoration of apatite-based chromatography resins
WO2014003142A1 (ja) * 2012-06-27 2014-01-03 旭化成メディカル株式会社 抗体
JP2014105180A (ja) * 2012-11-27 2014-06-09 Hoya Corp モノマー化方法
WO2014160371A1 (en) 2013-03-13 2014-10-02 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
EP2997041A4 (en) * 2013-05-13 2017-02-15 Medlmmune, LLC Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
JP2016532100A (ja) 2013-07-05 2016-10-13 ラボラトワール・フランセ・デュ・フラクシオンマン・エ・デ・ビョテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ アフィニティークロマトグラフィーマトリックス
CN105324166B (zh) 2013-07-12 2018-01-19 默克专利股份有限公司 利用活性炭从包含靶蛋白的样品去除片段
JP6479305B2 (ja) * 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
SG10201804200WA (en) 2013-12-12 2018-07-30 Emd Millipore Corp Protein separations using an acrylamide containing filter
TWI787590B (zh) * 2013-12-27 2022-12-21 日商中外製藥股份有限公司 等電點低之抗體的精製方法
EP3157551B1 (en) 2014-06-23 2023-02-15 Bio-Rad Laboratories, Inc. Apatite in-situ restoration
CN105392569B (zh) 2014-06-23 2019-08-20 生物辐射实验室股份有限公司 磷灰石预处理
SG11201704822WA (en) 2014-12-15 2017-07-28 Merck Patent Gmbh Target molecule capture from crude solutions
AU2016233557B2 (en) 2015-03-13 2021-06-24 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
US11661438B2 (en) 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
US11919924B1 (en) * 2016-03-15 2024-03-05 Fresenius Kabi Deutschland Gmbh Methods of purifying and producing an adalimumab antibody
CN106977591B (zh) * 2017-05-04 2020-05-05 广州康盛生物科技股份有限公司 一种分离纯化重组葡萄球菌蛋白a的方法
EP3672981A4 (en) 2017-08-22 2021-09-15 Biogen MA Inc. METHOD OF PURIFYING ANTIBODIES WITH AGGREGATES WITH REDUCED HIGH MOLECULAR WEIGHT
WO2019116096A1 (en) * 2017-12-15 2019-06-20 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Production of fc fragments
JP7449041B2 (ja) * 2018-02-27 2024-03-13 ファイザー・インク 抗体精製
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
JP2021519339A (ja) 2018-04-03 2021-08-10 メルク パテント ゲーエムベーハー Ｃｅｘクロマトグラフィー媒体及び生物製剤供給原料からの標的タンパク質の低塩溶出
JP6951051B2 (ja) * 2018-05-24 2021-10-20 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 吸着剤の生産方法
IL293047A (en) 2019-11-22 2022-07-01 Morphosys Ag A method for increasing antibody yield during ion exchange chromatography
JP2020099909A (ja) * 2020-03-17 2020-07-02 ＨＯＹＡ Ｔｅｃｈｎｏｓｕｒｇｉｃａｌ株式会社 処理方法、生産方法およびハイドロキシアパタイト充填剤
US20230136595A1 (en) 2020-03-30 2023-05-04 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
CA3182368A1 (en) * 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US428894A (en) 1890-05-27 Process of making tool-handles
US514018A (en) 1894-02-06 Edward j
US523335A (en) 1894-07-24 Air-bolt for flour-mills
US419964A (en) 1890-01-21 Transom-lifter
US4745183A (en) * 1984-02-21 1988-05-17 Bio-Rad Laboratories, Inc. Use of hydroxylapatite for the analysis and preparation of purified monoclonal antibodies
JPH03291300A (ja) * 1989-12-28 1991-12-20 Mitsui Toatsu Chem Inc ポリクローナル抗体の分離方法
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002359816B2 (en) 2001-12-21 2006-07-13 Immunex Corporation Methods for purifying protein
PT1601697E (pt) 2003-02-28 2007-09-04 Lonza Biologics Plc Purificação de anticorpos através de proteína a e cromatografia de troca iónica.
CA2543193C (en) * 2003-10-27 2015-08-11 Wyeth Removal of high molecular weight aggregates using hydroxyapatite chromatography

Also Published As

Publication number Publication date
CA2543193A1 (en) 2005-05-19
JP5004586B2 (ja) 2012-08-22
AU2004286938A1 (en) 2005-05-19
KR101321876B1 (ko) 2013-10-28
US9469672B2 (en) 2016-10-18
NZ547315A (pt) 2008-07-31
CN102276717B (zh) 2015-09-09
ECSP066583A (es) 2006-10-17
IL175229A (en) 2013-08-29
AU2004286938B2 (en) 2011-06-30
RU2010139827A (ru) 2012-03-27
PL1678208T3 (pl) 2013-09-30
ES2530446T3 (es) 2015-03-02
US20050107594A1 (en) 2005-05-19
EP1678208B1 (en) 2013-05-15
EP2336172A1 (en) 2011-06-22
JP2007532477A (ja) 2007-11-15
KR20060120163A (ko) 2006-11-24
JP5490156B2 (ja) 2014-05-14
PT1678208E (pt) 2013-07-10
RU2006113695A (ru) 2007-12-10
EP2336172B1 (en) 2014-12-10
RU2409591C2 (ru) 2011-01-20
CA2543193C (en) 2015-08-11
US20130197198A1 (en) 2013-08-01
RU2573910C2 (ru) 2016-01-27
WO2005044856A2 (en) 2005-05-19
IL175229A0 (en) 2006-09-05
WO2005044856A3 (en) 2005-06-23
BR122020007658B1 (pt) 2021-07-27
MXPA06004472A (es) 2006-06-20
JP2012111769A (ja) 2012-06-14
CN1898266B (zh) 2011-09-21
CN1898266A (zh) 2007-01-17
ES2418830T3 (es) 2013-08-16
CN102276717A (zh) 2011-12-14
PL2336172T3 (pl) 2015-04-30
EP1678208A2 (en) 2006-07-12
PT2336172E (pt) 2015-02-20
KR20120003027A (ko) 2012-01-09
CO5690649A2 (es) 2006-10-31
US9822143B2 (en) 2017-11-21
DK2336172T3 (en) 2015-01-26
KR101221862B1 (ko) 2013-01-14
BRPI0415887B1 (pt) 2021-01-26
DK1678208T3 (da) 2013-07-08

Similar Documents

Publication Publication Date Title
BRPI0415887A (pt) remoção de agregados de elevado peso molecular usando cromatografia de hidroxiapatita
SE0101675D0 (sv) Novel composition
DK1379239T3 (da) N(2-aryl-ethyl)-benzyl-aminer som antagonister af 5 HT6 receptoren
BRPI0411552A (pt) anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
BRPI0411535A (pt) composições e métodos para aumentar a mineralização óssea
CR9377A (es) Un metodo de cromatografia de particion debil
BRPI0517973A (pt) método para purificar o fsh
SE0203713D0 (sv) Novel compounds
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
BR0313733A (pt) Uso da proteìna n beta cinase
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
CL2003001814A1 (es) Compuestos derivados de 1,3,8-triazaespiro[4,5]decan-4-ona jidroxialquil sustituidos, moduladores del receptor orl-1; compuestos intermediarios; composicion farmaceutica que contiene dichos compuestos; procedimiento de preparacion de la composicion f
BR0213207A (pt) remodelagem e glicoconjugação de peptìdeos
HN1998000157A (es) Agonistas de prostaglandinas
CY1106468T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
DE60237528D1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
BRPI0414634A (pt) agonistas de receptor b2, adrenérgico de etilamino amino-substituìdo
WO2003048207A3 (en) Anti-dota antibody
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
BRPI0417992A (pt) método para purificar fsh
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.